Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Abstract: An electromagnetic sensing device comprising: a reference microfluidic reservoir to receive a reference substance with magnetic nanoparticles; an analyte microfluidic reservoir to receive an analyte and magnetic nanoparticles; a first excitation magnetic coil to subject the reference microfluidic reservoir to an alternating magnetic field at a first frequency; a second excitation magnetic coil to subject the analyte microfluidic reservoir to an alternating magnetic field at the first frequency; a third excitation magnetic coil to subject the reference microfluidic reservoir to an alternating magnetic field at a second frequency distinct from the first frequency; a fourth excitation magnetic coil to subject the analyte microfluidic reservoir to an alternating magnetic field at the second frequency; a first detection magnetic coil to detect a response magnetic field of the magnetic nanoparticles in the reference microfluidic reservoir; a second detection magnetic coil to detect a response magnetic field of the

Abstract: A complementation system including two fragments of photoactive yellow protein (PYP), or truncated fragments thereof, and its use with a fluorogenic hydroxybenzylidene rhodanine (HBR) analog for detecting interactions between biological molecules of interest, in particular between proteins of interest. Especially, a complementation system including a first PYP fragment having an amino acid sequence having at least about 70% identity with the amino acid sequence of SEQ ID NO: 23, or a truncated fragment thereof including at least 89 consecutive amino acids from the C-terminal end of the amino acid sequence; and a second PYP fragment having an amino acid sequence having at least about 70% identity with the amino acid sequence of SEQ ID NO: 34, or a truncated fragment thereof including at least 8 consecutive amino acids of the amino acid sequence, preferably 8 consecutive amino acids from the N-terminal end of the amino acid sequence.

Abstract: Systems, instruments, and methods are provided verifying that a robotic surgery is being performed in accordance with a surgical plan, wherein a surgical tool having a sensor outputs a data signal that enables the trajectory of the surgical tool to be displayed as an overlay on an image of an anatomical portion of a patient and a visual or audible signal that confirms the surgical tool is penetrating the anatomical portion in accordance with the surgical plan and/or that issues an alert indicating that the surgical tool is not being inserted into the anatomical portion according to the surgical plan.

Abstract: A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases. A compound of formula (I): wherein R1 is a (C1-C4) alkyl group, or a (C3-C6) cycloalkyl group, R2 is a phenyl or a substituted phenyl with one to three groups, with the proviso that when R2 is a phenyl then R1 is a (C3-C6) cycloalkyl group, or anyone of its pharmaceutically acceptable salt. Also, the compound of formula (I) as medicament for treating rare biliary diseases such as intrahepatic cholestatic diseases.

Abstract: The present invention concerns a method for the 3D reconstruction of a scene comprising the matching (610) of a first event from among the first asynchronous successive events of a first sensor with a second event from among the second asynchronous successive events of a second sensor depending on a minimisation (609) of a cost function (E).

Abstract: The present invention concerns an objective (10) for imaging an object field of view of 10° onto an imager (12), the objective (10) comprising in order of the propagating direction: —a first lens unit (U1) comprising several lenses, the first lens unit (U1) having a positive first focal length and a first dimension inferior to 15 millimeters, —a bending mirror (M) adapted to bend at a 90° angle, —a liquid lens (LL), and —a second lens unit (U2) comprising several lenses, the second lens unit (U2) having a positive second focal length and a second dimension, the ratio between the first focal length and the second focal length being comprised between 1.0 and 2.0 and the ratio between the first dimension and the second dimension being superior or equal to 2.

Abstract: The present invention relates to an electrolysis device comprising an anode and a cathode, wherein the anode and the cathode each are an electrode comprising an electrically conductive support of which at least a part of the surface is covered by a metal deposit of copper, wherein the surface of the metal deposit is in an oxidized, sulfurated, selenated and/or tellurized form and the metal deposit has a specific surface area greater than or equal to 1 m2/g. The present invention relates also to a method for reducing CO2 into hydrocarbons using an electrolysis device according to the invention. The method according to the invention comprises: a) providing an electrolysis device according to the invention; b) exposing the cathode of said electrolysis device to a CO2-containing aqueous catholyte solution; c) exposing the anode of said electrolysis device to an aqueous anolyte solution; and d) applying an electrical current between the anode and the cathode in order to reduce the carbon dioxide into hydrocarbons.

Abstract: The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.

Abstract: The invention relates to a virus-like particle comprising an autoantigen and an immunoregulatory molecule exposed on its surface. The invention also relates to the use of said particle in the treatment of an autoimmune disease.

Abstract: The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.

Abstract: The present invention relates to an inductive dipole element for a superconducting microwave quantum circuit. The dipole element comprises a DC-SQUID formed by a pair of Josephson junctions shunted by an inductance, wherein the Josephson junctions have equal energy, and the Josephson junctions and the inductance are arranged such that each of the junctions forms a loop with the inductance. The two loops are asymmetrically threaded with external magnetic DC fluxes ?ext1 and ?ext2, respectively, such that ?ext1=? and ?ext2=0, wherein parametric pumping is enabled by modulating the total flux ??=?ext,1+?ext,2 threading the dipole element, thereby allowing even-wave mixing between modes that participate in the dipole element with no Kerr-like interactions.

Abstract: A local anesthetic chosen from the group of amino amide or amino ester, and a composition or pharmaceutical composition including the local anesthetic. The local anesthetic is for use in the treatment of neurological symptoms resulting from brain dysfunctions such as motor, cognitive, sensory, visual deficits, and/or apathetic, catatonic, vegetative and/or minimally conscious states.

Abstract: A system to measure and monitor neurodegeneration of a subject, which includes: an acquisition module configured to acquire electroencephalographic signals with multiple EEG channels from a subject perceptually isolated; a calculation module configured to extract at least one EEG metric representative of neurodegeneration; and an evaluation module configured to evaluate the at least one EEG metric and extract a neurodegeneration index.

Abstract: Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding the 5 CFTR Cl— channel and affects several organs, but the most severe consequences are observed in the lung. The inventors have now instigated the combination of Orkambi® and ANO1 TSB (SEQ ID NO:1) and show that said combination increases mucociliary clearance and chloride channel activity. Thus the combination represents an alternative treatment for CF subjects.

Abstract: An in-ear stimulation system including a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject. Each of the first device and the second device includes: at least one in-ear active electrode configured to receive a bio-signal and at least one in-ear reference electrode configured to receive a bio-signal; at least one stimulation device configured for emitting at least one electrical or sensory stimulus; and an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

Abstract: The present invention relates to a microfluidic or millifluidic device (1) comprising: —a support (2) made at least partially of a dielectric material, the support (2) comprising a first inlet (21a) adapted to be connected to a first reservoir containing gas, a second inlet (21b) adapted to be connected to a second reservoir containing liquid, an outlet (22) adapted to be connected to a receiver container containing gas and/or liquid, and a main microchannel or millichannel (3) present in the dielectric material allowing the liquid and the gas to flow from the inlets towards the outlet, —one or several ground electrode(s) (4) embedded in said dielectric material and extending along the main microchannel or millichannel (3), and —one or several high-voltage electrode(s) (5) embedded in said dielectric material and extending along the main microchannel or millichannel (3), wherein the high-voltage electrode(s) (5) and the ground electrode(s) (4) are located on opposite sides of the main microchannel or millicha

Abstract: An external ultrasound generating treating device (12) to induce spinal cord and/or spinal nerve treatment comprises at least two sub-arrays of ultrasound generating treatment transducers, a left sub-array (20iL) being located on a left lateral side and a right sub-array (20iR) being located on a right lateral side of the central longitudinal axis (Ai). The device comprises a support structure (32) having at least one module (34i) comprising a left lateral section (34iL) and a right lateral section (34iR). The support structure (32) maintains, in use of the device, a constant distance and a constant relative angular orientation around the central longitudinal axis (Ai) between the first left and first right treatment transducers or set of treatment transducers (20iL, 20iR). Also disclosed is an apparatus including the external ultrasound generating treating device (12) and methods of its use.

Abstract: The present invention relates to a device (1) for sintering by pulsating current, the device (1) comprising: —a sintering cell (4) comprising two walls (14a, 14b) facing each other and defining between them a cavity (C) for receiving material to be sintered, —a press (2) arranged for moving one of the walls (14a, 14b) towards the other wall, so as to compress the material, when the material is received in the cavity (C), —means (10a, 10b) of rotating one of the walls (14a, 14b) relative to the other wall, so as to apply a torsional force to the material, when the material is compressed in the cavity (C).

Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).